New prospective in treatment of Parkinson’s disease: Studies on permeation of ropinirole through buccal mucosa

Flavia Maria Sutera, Libero Italo Giannola, Viviana De Caro, Giannola, Giulia Giandalia, Maria Gabriella Siragusa

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

The aptitude of Ropinirole to permeate the buccal tissue was tested using porcine mucosa mounted on Franz-type diffusion cells as ex vivo model. Drug permeation was also evaluated in presence of various penetration enhancers and in iontophoretic conditions.Ropinirole, widely used in treatment of motor fluctuations of Parkinson’s Disease, passes the buccal mucosa. Flux and permeability coefficient values suggested that the membrane does not appear a limiting step to the drug absorption. Nevertheless, an initial lag time is observed but the input rate can be modulated by permeation enhancement using Limonene or by application of electric fields. Absorption improvement was accompanied by the important reduction of the lag time; at once the time required to reach the steady state plasma concentration was drastically decreased. On the basis of these results we could assume that clinical application of Ropinirole by buccal delivery is feasible
Original languageEnglish
Pages (from-to)78-83
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume429
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'New prospective in treatment of Parkinson’s disease: Studies on permeation of ropinirole through buccal mucosa'. Together they form a unique fingerprint.

Cite this